免疫检查点抑制剂治疗中急性血管事件作为可能相关不良事件的单中心回顾性研究
该单中心回顾性研究纳入2015年1月至2018年5月在以色列Sheba医疗中心接受免疫检查点抑制剂(CPI)治疗的1215例患者,评估急性血管事件(AVE)风险。结果显示CPI启动后6个月内AVE发生率为2.6%(95%CI 1.8-3.6),肺腺癌患者为5.2%(95%CI 2.8-9.2);肺腺癌、既往AVE、高血压和高脂血症与AVE相关;非小细胞肺癌腺癌患者中CPI与化疗的AVE发生率相似;发生AVE者生存更差。
要点
- CPI启动后6个月内AVE发生率为2.6%,肺腺癌患者为5.2%,均高于后续时间段。
- 肺腺癌、既往AVE、高血压和高脂血症与AVE发生相关。
- 非小细胞肺癌腺癌患者中,CPI与化疗的AVE发生率相似,发生AVE者生存更差。
核心结论
- CPI可能并未在化疗基础上额外增加AVE风险,但两者均带来相似且显著的AVE风险。
- 对存在AVE危险因素的患者应谨慎。
研究设计与样本
- 单中心回顾性研究,从电子病历中识别2015年1月至2018年5月在以色列Sheba医疗中心接受CPI治疗的患者,共1215例。
- 通过病历回顾识别并核实AVE,评估年龄、性别、糖尿病、高血压、吸烟、高脂血症、既往AVE、肾功能衰竭、肿瘤类型及具体治疗等潜在危险因素。
- 在肺腺癌患者中比较CPI与化疗或化疗联合免疫治疗的AVE发生率,并比较发生AVE与未发生AVE患者的生存。
主要发现
- CPI启动后6个月内AVE发生率为2.6%(95%CI 1.8-3.6),高于后续时间段。
- 肺腺癌患者AVE事件率为5.2%(95%CI 2.8-9.2)。
- 肺腺癌、既往AVE、高血压和高脂血症与AVE相关。
- 非小细胞肺癌腺癌患者中,化疗与CPI的AVE发生率相似。
- 发生AVE的患者生存劣于未发生AVE的患者。
关键数值与推荐
- CPI启动后6个月内AVE发生率2.6%(95%CI 1.8-3.6)。
- 肺腺癌患者AVE事件率5.2%(95%CI 2.8-9.2)。
- 肺腺癌、既往AVE、高血压和高脂血症与AVE相关。
- 非小细胞肺癌腺癌患者中化疗与CPI的AVE发生率相似。
临床怎么用
- 对接受CPI治疗的患者,尤其合并肺腺癌、既往AVE、高血压或高脂血症者,应警惕急性血管事件。
- 非小细胞肺癌腺癌患者选择CPI或化疗时,两者AVE风险相似,均需关注血管不良事件。
- 发生AVE可能提示预后不良,应加强监测与处理。
局限性
- 单中心回顾性研究,结论需外部验证。
- AVE通过病历回顾识别,可能存在漏诊或误判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Immune-related toxicities of immune checkpoint inhibitors (CPIs) require prompt diagnosis and treatment. Atherosclerosis has an inflammatory component; we speculated this inflammation could be enhanced by CPIs. We aimed to evaluate the risk of acute vascular events (AVEs) on CPIs. METHODS: Patients treated by CPIs in Sheba Medical Center (Israel) between January 2015 and May 2018 were retrospectively identified from electronic medical records. AVEs were identified and verified by chart review. Age, sex, diabetes, hypertension, smoking, dyslipidemia, previous AVE, renal failure, cancer type and specific treatments were evaluated as potential risk factors. AVE rate on CPIs was compared with that on chemotherapy or on combined chemo-immunotherapy in patients with lung adenocarcinoma. Survival of patients with AVEs was compared with that of patients without AVEs. RESULTS: CPI was administered to 1215 patients. AVEs within six months after CPI initiation occurred in 2.6% (95% confidence interval [CI]: 1.8-3.6) of patients, more common than in later time periods. In lung adenocarcinoma, event rate was 5.2% (95% CI: 2.8-9.2). Lung adenocarcinoma, prior AVE, hypertension and dyslipidemia were correlated with AVEs. AVE rate in patients with non-small cell lung cancer adenocarcinoma was similar whether on chemotherapy or on CPI. Survival of patients with AVEs was worse than that of those without AVEs. CONCLUSION: The similarly increased rates of AVEs for patients on CPI, on chemotherapy or on both suggest that although CPI may not augment the risk of AVE over that of chemotherapy, it carries a similar and significant risk of such adverse event. Caution should be exercised for patients with risk factors for AVEs.
引用
- Bar J, Markel G, Gottfried T, et al. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019. PMID: 31518968. doi:10.1016/j.ejca.2019.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。